Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study

Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study

The subsequent maintenance therapy in chronic hepatitis B (CHB) patients after long-term viral replication suppression is still uncertain. We aim to evaluate the efficacy of lamivudine (LAM) maintenance therapy in CHB patients achieving undetectable hepatitis B virus (HBV) DNA after 3 years of entec...

Full description

Bibliographic Details
Main Authors: Ming-Lun Yeh, Ching-I. Huang, Ming-Yen Hsieh, Chung-Feng Huang, Meng-Hsuan Hsieh, Jee-Fu Huang, Chia-Yen Dai, Zu-Yau Lin, Shinn-Chern Chen, Ming-Lung Yu, Wan-Long Chuang
Format: Article
Language:English
Published: Wiley 2016-11-01
Series:Kaohsiung Journal of Medical Sciences
Subjects:
Chronic hepatitis B
Entecavir
Lamivudine
Relapse
Switch
Online Access:http://www.sciencedirect.com/science/article/pii/S1607551X16301978

Similar Items

Similar Items